Open Orphan Plc
ORPH.LN
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands. Open Orphan is led by a management team with deep industry and financial experience.
Related content
Analysis: Strong outlook for Open Orphan on UK Government contract and wider portfolio progress
The outlook for pharmaceutical services company Open Orphan (LSE:ORPH) has never looked stronger following the announcement of a Covid-19...
Open Orphan reveals transformational Covid-19 vaccine contract with UK government
Open Orphan hits record highs after winning £4.3m vaccine contract
Round-up: Busy week for Open Orphan as it pushes forward Covid and oncology arms (ORPH)
Open Orphan courts more major pharma backing with £4m RSV contract
Open Orphan announces major contract for Covid-19 vaccine trial (ORPH)
Key human challenge expert Adrian Wildfire rejoins hVIVO for Open Orphan boost (ORPH)
Open Orphan’s hVIVO expands lab growth revenue with three new contract wins (ORPH)
Open Orphan hits accumulation stage with operational profitability slated for Q3 2020 (ORPH)
Open Orphan signs new vaccine contract with “world leading” pharma player (ORPH)
Open Orphan launches Covid-19 antibody test (ORPH)
Open Orphan raises £12 million to boost Covid-19 operations (ORPH)
Open Orphan share price spikes as Covid-19 home testing stocks rocket (ORPH)
The remarkable rise of rare and orphan drug producer Open Orphan (LSE:ORPH) continues with the confirmation of a new Covid-19 antibody test.
VIDEO: Open Orphan’s Cathal Friel on firm’s ambitious plans in the coronavirus vaccination space
Open Orphan’s rapid growth continues with Covid-19 antibody test deal (ORPH)
Open Orphan races ahead with £3.5m US human challenge study contract (ORPH)
Sign up for VTM Updates
Top Picks for Q2 2022
View MoreCrypto Corner
Learn your NFTs from your BTCs